Leadership & Pay ·
On June 26, 2026, Tenax Therapeutics adopted a Change in Control (CIC) Plan and a Severance Plan providing cash…
TENXTenax Therapeutics, Inc.
On June 26, 2026, Tenax Therapeutics adopted a Change in Control (CIC) Plan and a Severance Plan providing cash severance and equity acceleration to eligible employees. Simultaneously, the Board approved amendments to the employment agreements of Christopher Giordano, Thomas Staab, and Stuart Rich to align their severance and change-in-control benefits with these new plans. For terminations without Cause, these executives receive 12 to 24 months of base salary, pro-rated bonuses, and 12 months of COBRA. In a Change in Control event, benefits increase to 12 to 18 months of salary and COBRA, full annual bonuses, and accelerated equity vesting. Tenax Therapeutics is a biotechnology company that develops therapeutic treatments.